Staley A. Brod, M.D.

Professor of Neurology

Contact Information:

Phone: 713-500-7135
Fax: 713-500-7040
E-mail: Staley.A.Brod@uth.tmc.edu

Board Certifications

American Board of Psychiatry and Neurology in Neurology
American Board of Internal Medicine in Internal Medicine

Education and Training:

Undergraduate: Western Reserve Academy, A.B. Williams College - Major in Philosophy/Chemistry
Medical School: University of Toledo, Ohio
Internal Medicine Residency: Medical College of Ohio
Neurology Residency: Yale-New Haven Medical Center, Yale University Medical School
Research and Clinical Neurology Fellowship: Center for Neurologic Disease, Brigham and Women’s Hospital, Harvard Medical School, Boston

Clinical & Research Interests

He is currently investigating the use of oral interferon in multiple sclerosis and type 1 diabetes. He has just finished a clinical trial in MS patients that shows that very low doses change biomarkers in the blood without absorption of the interferon into the bloodstream. He is also the principal investigator of a trial investigating ingested interferon alpha in the preservation of residual beta cell function in newly diagnosed type I diabetes mellitus in conjunction with Kristina I. Rother, M.D., NIH/NIDDK.

Research Interests: Animal models of auto-immune disease; immunomodulation; oral administration of SIRS peptide (soluble immune response suppressor); counter regulatory cytokines; multiple sclerosis (MS), insulin dependent diabetes mellitus (TYPE 1 DIABETES).

The research in my laboratory is directed at understanding the underlying immune abnormalities of human auto-immune disease. Current studies are directed at understanding the mechanism of inflammation in the NOD mouse model of TYPE 1 DIABETES and EAE the mouse model for MS and determining which cells are responsible for its suppression.

Biography

Staley A. Brod, M.D., has been a Professor of Neurology at the University of Texas Health Science Center at Houston School of Medicine since 2002. Dr. Brod graduated from Williams College with a degree in Philosophy in 1972 and attended medical school in Belgium at the Rijksuniversitair Centrum Antwerpen and the Universitair Instelling Antwerpen from 1974 to 1979. He obtained his Doctor of Medicine degree from the Medical College of Ohio in 1981. He completed residencies in Internal Medicine and Neurology at the Medical College of Ohio and the Yale-New Haven Medical Center at Yale University Medical School respectively and is board certified in both Internal Medicine and Neurology.

He was a Research and Clinical Fellow in Neurology at the Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School from 1987-1990, an Associate Physician in Neurology at Brigham and Women's Hospital and an Instructor in Neurology (Medicine) at the Harvard Medical School from 1990-1991. Following his fellowship training, Dr. Brod became an Assistant Professor of Neurology in Division of Neuroimmunology, University of Texas Southwestern Medical School in Dallas from 1991-93 and subsequently an Professor of Neurology in the MS Research Group at the University of Texas Health Science Center at Houston School of Medicine in 2002.

He follows 750 patients with multiple sclerosis and is the principal investigator for four phase II & IV clinical trials in multiple sclerosis. Dr. Brod is a member of the American Academy of Neurology and the International Society for Interferon and Cytokine Research and a reviewer for Neurology, Archives of Neurology, the Scandanivian Journal of Immunology, the Journal of Autoimmunity, and the Journal of Neuroimmunology and Diabetologia. Dr. Brod has published over 100 abstracts and papers on the use of ingested type I interferon in humans and animal models of autoimmune disease. He was the Barbara Jordan Research Award winner from the National Multiple Sclerosis Society to study the mechanism underlying the passive transfer of resistance to EAE from donors ingesting IFN-?, is a co-investigator of a grant investigating the basic mechanisms of multiple sclerosis funded by the Clayton Foundation, and NIH awardee to evaluate the biologic effects of oral interferon alpha in relapsing-remitting multiple sclerosis.

Recent Publications

KI Rother, RJ Brown, M. Morales, E. Wright, Z. Duan, C Campbell, DM Harlan, PR Orlander, SA Brod. Ingested IFN-Alpha2a Prolongs the ‘Honeymoon’ Phase in New Onset Type 1 Diabetes Mellitus (T1D) in a phase II Randomized clinical trial (RCT). 10th IDS Congress. Malmo, Sweden, May 2009.
Brod SA, Z Hood. 2008. Evaluation of Plasma Cortisol Concentrations after Subcutaneous and Intramuscular Administration of H.P. Acthar® Gel in Healthy Volunteers. Biomed & Pharmacother Sept 17, pg 1-3.
K Rother, D. Harlan, Dana Hardin, Philip Orlander, Patrick Brosnan, Victor Lavis, S. Brod. Ingested Interferon Alpha: Prolongation or Permanence of the ‘Honeymoon’ Phase in Newly Diagnosed Diabetes Mellitus. Diabetes Care 32(7): 1250-5.
Brod SA, Khan M, Nelson LD, Decuir B, Malone M, and Henninger E. Adoptive Transfer of Activated T and CD8+ T cells from Murine IFN-??Fed Donor Mice Inhibits Actively Induced Experimental Autoimmune Encephalomyelitis in Recipients and is Associated with Decreasing TNF-? Secretion. J. Immunother. 2000; 23(2): 235-245.
Brod S, JW Lindsey, and JS Wolinsky. Combination Therapy with Glatirimer Acetate (Copolymer-1) and a Type I Interferon (IFN-?) Does Not Improve Experimental Autoimmune Encephalomyelitis. Ann Neurol 2000;47: 127-131.
Brod S, Phan T, Katz S, and Stepkowski S. Ingested IFN-b delays islet allograft rejection. Transplantation. 2000; 69 (10), 2162-6.
Brod SA. 2000. Unregulated Inflammation Shortens Human Functional Longevity. Inflammation Res 49:561-70.
Brod SA. Friedman AW, Appleyard J, Warner NB. 2000. Ingested IFN-b has biological effects in rheumatoid arthritis. Int. J Immunother 16 (3-4), 53.
Brod SA, Lindsey JW, Vriesendorp FS, Ahn C, Narayana PA, Wolinsky JS. 2001. Ingested IFN-a: Results of a pilot study in relapsing-remitting multiple sclerosis (RRMS). Neurology 57 (5): 845-852.
Brod S, Orlander P, Lavis V, Brosnan P, Hardin D, Henninger E, and Riley W. 2001. Ingested IFN-a ?prolongs the “honeymoon” period in newly diagnosed type I diabetes mellitus. J Interferon Cyt Res 21 (11), 1021-1030.
Brod SA. 2002. Ingested Type I Interferon – State of the art in the Treatment of Autoimmunity. Experimental Biology and Medicine 227(11): 981-8.
Brod SA. 2002. Ingested Type I Interferon – A Potential Treatment for Autoimmunity. J Interferon Cyt Res 22 (12) pp 1153-1166.
Brod SA, M Nguyen, Z Hood, G Shipley. 2006. Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. J Interferon Cyt. Res. Mar;26(3):150-5.
Brod SA, Z Hood. 2007. Ingested (oral) SIRS Peptide 1-21 Inhibits Acute EAE By Inducing Th2-like Cytokines. J Neuroimmunol Feb 183 (1-2): 89-95.
Brod SA, Z Hood. 2008. Ingested (oral) SIRS Peptide 1-21 Suppresses T1DM in NOD mice. J Interferon Cyt Res 28 (1): 25-30.
Brod SA, Z Hood. Ingested (oral) alpha-MSH Inhibits Acute EAE. 2008. J Neuroimmunol. 193: 106-112.
Brod SA, Z Hood. Evaluation of Plasma Cortisol Concentrations after Subcutaneous and Intramuscular Administration of H.P. Acthar® Gel in Healthy Volunteers. In preparation.
K Rother, D. Harlan, Dana Hardin, Philip Orlander, Patrick Brosnan, Victor Lavis, S. Brod. Ingested Interferon Alpha: Prolongation or Permanence of the ‘Honeymoon’ Phase in Newly Diagnosed Diabetes Mellitus. In preparation.

Patents

D-6380 — USPTO
USSN 10/655, 164
Filed 9/4/03
Notice of Allowance
“Treatment of Cognitive Decline”
D-5716 Australia
Australian Patent Application No. 22839/95
“Method of Treating Auto-Immune Diseases Using Type One Interferons”
D-5716 South Africa
South African Patent Application No. 95/2797
“Method of Treating Auto-Immune Diseases Using Type One Interferons”
D-5716 New Zealand
New Zealand Patent Application No. 284276
“Method of Treating Auto-Immune Diseases Using Type One Interferons”
D-5716 Russia
Russian Patent Application No. 284276
“Method of Treating Auto-Immune Diseases Using Type One Interferons”
D-5716 CIP5
USPTO USSN 09/314,503
“Method of Treating Auto-Immune Diseases Using Type One Interferons”
Inhibition of Transplant Rejection by Type I Interferon.
Patent Number 6,346,243